Showing results (601-610 of 634) with videos related to

Sort By:
Pageof 64
Nucleic Acids Research|May 12, 2019
Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primatesMichael E Østergaard, Michaela Jackson, Audrey Low, et al.
Cancer Research and Treatment|July 12, 2024
The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study GroupBum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, et al.
Investigational New Drugs|August 8, 2017
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testingKyoungmin Lee, Changhoon Yoo, Kyu-Pyo Kim, et al.
BMC Cancer|November 27, 2014
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trialSeung Tae Kim, Yong Sang Hong, Ho Yeong Lim, et al.
JAMA Network Open|October 19, 2020
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT TrialBenoist Chibaudel, Julie Henriques, Manel Rakez, et al.
European Radiology|September 17, 2022
FDG metabolic parameter-based models for predicting recurrence after upfront surgery in synchronous colorectal cancer liver metastasisHyo Sang Lee, Hyun Woo Kwon, Seok-Byung Lim, et al.
Nature Communications|September 23, 2023
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancerLucia Taraborrelli, Yasin Şenbabaoğlu, Lifen Wang, et al.
Oncotarget|August 29, 2015
A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancerJai-Hee Moon, Jae-Sik Shin, Seung-Woo Hong, et al.
JAMA Oncology|September 28, 2023
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled TrialTae Won Kim, Philippe L Bedard, Patricia LoRusso, et al.
The Lancet. Oncology|September 10, 2014
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trialYong Sang Hong, Byung-Ho Nam, Kyu-Pyo Kim, et al.
Pageof 64